Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients was assessed for gene mutations. Patients received azacitidine 75 mg/m2/day x7 days (n = 240) or conventional care regim...
Үндсэн зохиолчид: | Döhner, H, Dolnik, A, Tang, L, Seymour, JF, Minden, MD, Stone, RM, Del Castillo, TB, Al-Ali, HK, Santini, V, Vyas, P, Beach, CL, Macbeth, KJ, Skikne, BS, Songer, S, Tu, N, Bullinger, L, Dombret, H |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
Springer Nature
2018
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Azacitidine prolongs overall survival in older patients with Acute Myeloid Leukemia (AML) with poor prognostic karyotypes
-н: Doehner, H, зэрэг
Хэвлэсэн: (2017) -
Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR)
-н: Doehner, H, зэрэг
Хэвлэсэн: (2016) -
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
-н: Andrew H. Wei, зэрэг
Хэвлэсэн: (2023-03-01) -
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
-н: John F. Seymour, зэрэг
Хэвлэсэн: (2017-12-01) -
P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-001 TRIAL OF ORAL AZACITIDINE
-н: A. H. Wei, зэрэг
Хэвлэсэн: (2022-06-01)